Kyohei Nishida

Kyohei Nishida

Auto-generated profile, based on publicly available information

Kyohei Nishida

Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2019 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
TTToshikazu Tanaka
Toshikazu Tanaka
TMTakehiko Matsushita
Takehiko Matsushita
KNKyohei Nishida
Kyohei Nishida
KTKoji Takayama
Koji Takayama
KNKanto Nagai
Kanto Nagai
RKRyosuke Kuroda
Ryosuke Kuroda

13 August 2021 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
PDF file
KNKyohei Nishida
Kyohei Nishida
CXCaiqi Xu
Caiqi Xu
TGTom Gale
Tom Gale
WAWilliam Anderst
William Anderst
FFFreddie Fu
Freddie Fu

15 October 2022 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
KNKoji Nukuto
Koji Nukuto
TMTakehiko Matsushita
Takehiko Matsushita
KKKohei Kamada
Kohei Kamada
KNKyohei Nishida
Kyohei Nishida
KNKanto Nagai
Kanto Nagai
RKRyosuke Kuroda
Ryosuke Kuroda

29 June 2025 in Connective Tissue Research
Verified
Journal Article
Closed access
YOYuhei Otsuki
Yuhei Otsuki
TMTakehiko Matsushita
Takehiko Matsushita
AMAkiyoshi Mori
Akiyoshi Mori
NMNobuaki Miyaji
Nobuaki Miyaji
TYTetsuya Yamamoto
Tetsuya Yamamoto
RKRyosuke Kuroda
Ryosuke Kuroda
Temsirolimus is a water-soluble mammalian target of rapamycin (mTOR) complex inhibitor, potentially suitable for intra-articular administration. The present study aims to evaluate the therapeutic effects of intra-articular administration of temsirolimus on human chondrocytes and osteoarthritis (OA) progression in mice. The beneficial effects of temsirolimus treatment were evaluated in human chondrocytes (Normal Human Articular Chondrocyte-Knee cells) with or without treatment with IL-1β in vitro by real-time polymerase chain reaction, TUNEL staining for apoptosis, and CYTO-ID(R) staining for autophagy. The therapeutic effect of intra-articular injection of temsirolimus was evaluated in OA models (destabilized medial meniscus in C57BL/6J and senescence accelerated mice prone 8 (SAMP8)) in vivo, by histological and immunohistochemical analyses. Temsirolimus treatment upregulated COL2A1 and aggrecan (a major proteoglycan in the articular cartilage) expression in human chondrocytes. In addition, temsirolimus treatment recovered IL-1β-induced down-reregulated COL2A1 and aggrecan expression, while it partially decreased upregulated MMP-1, MMP-13, ADAMTS-4, ADAMTS-5, IL-1β, and IL-6 expression and apoptosis in human chondrocytes. Further, temsirolimus treatment enhanced autophagic activity in human chondrocytes. The intra-articular injection of temsirolimus to 12-week and 1-year old wild-type surgically induced OA model mice and SAMP8 mice delayed OA progression as compared to that in the control mice. Temsirolimus treatment protected human chondrocytes from IL-1β-induced OA gene expression changes and apoptosis. Intra-articular injection of temsirolimus delayed OA progression in the mouse OA model and in SAMP8 mice. Thus, the intra-articular administration of temsirolimus is a promising therapeutic approach to inhibit articular cartilage degradation.


9 November 2026 in Orthopaedic Journal of Sports Medicine
Verified
Journal Article
Open access
SYShin Yoshida
Shin Yoshida
YHYuichi Hoshino
Yuichi Hoshino
ATAtsuki Tanaka
Atsuki Tanaka
YOYuhei Otsuki
Yuhei Otsuki
YNYuta Nakanishi
Yuta Nakanishi
RKRyosuke Kuroda
Ryosuke Kuroda
Background: Ramp lesions and lateral meniscal oblique radial tears (LMORTs) have been suggested to influence knee laxity; however, dynamic changes associated with these lesions remain incompletely understood. Purpose: To quantitatively evaluate changes in knee laxity associated with the sequential addition of a ramp lesion and LMORT in anterior cruciate ligament (ACL)–deficient knees using whole cadaveric lower limbs. Study Design: Controlled laboratory study. Methods: Ten fresh-frozen cadaveric lower limbs were tested under 4 sequential conditions: ACL intact (ACLI), ACL deficient (ACLD), ACLD with a ramp lesion, and ACLD with a ramp lesion and LMORT. Knee laxity was quantitatively assessed with an electromagnetic sensor system. Anterior tibial translation (ATT) was measured during the Lachman test and anterior drawer test at 30°, 60°, and 90° of flexion, as were anterior-posterior tibial translation and posterior tibial acceleration during the pivot-shift test. Comparisons among the 4 conditions were performed by repeated measures analysis of variance, followed by paired t tests with Holm adjustment for multiple comparisons. Results: During the anterior drawer test at 60° of flexion, ATT increased from 7.6 ± 3.7 mm (mean ± SD) in the ACLI group to 9.5 ± 3.3 mm in the ACLD group and 10.5 ± 2.9 mm in the ramp group. ATT was significantly greater in the ramp group than in the ACLI group (mean paired difference, 2.9 mm; 95% CI, 1.7-4.0; P = .002). However, no statistically significant difference was detected between the ACLI and ACLD groups ( P = .064) or between the ACLD and ramp groups ( P = .161). After the addition of LMORT, posterior tibial acceleration during the pivot-shift test increased from 2.0 ± 1.0 to 2.9 ± 0.9 m/s 2 . Conclusion: In this sequential whole-limb model, a concomitant ramp lesion may contribute to anterior laxity at midflexion, while the subsequent addition of LMORT was associated with a further increase in posterior tibial acceleration during the pivot-shift maneuver. Clinical Relevance: These findings highlight the importance of considering concomitant ramp lesions and LMORTs when evaluating knee laxity in ACL-deficient knees.